Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial

被引：1
|
作者：
Paller, Amy [1 ]
Jett, John E. [2 ]
Hebert, Adelaide [3 ,4 ,5 ]
Brown, Philip M. [2 ]
Butners, Victoria [2 ]
Fitzgerald, Nancy [2 ]
Delgado, Marta [6 ]
Gonzalez, Mercedes E. [7 ]
Piscitelli, Stephen C. [2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] Dermavant Sci Inc, Morrisville, NC USA
[3] UTHealth McGovern, McGovern Sch Med, Houston, TX USA
[4] UTHealth McGovern, Childrens Mem Hermann Hosp, Houston, TX USA
[5] UTHealth McGovern Med Sch, Houston, TX USA
[6] RM Med Res Inc, Miami Lakes, FL USA
[7] Pediat Skin Res LLC, Miami, FL USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
atopic dermatitis; pediatrics; tapinarof; maximal usage trial;
D O I：
10.1093/bjd/ljad162.028
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
406
引用
收藏
页数：2
相关论文
共 38 条
  • [31] Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis
    Simpson, Eric
    Boguniewicz, Mark
    Eichenfield, Lawrence
    Gonzales, Mercedes E.
    Hebert, Adelaide A.
    Prajapati, Vimal H.
    Gooderham, Melinda
    Krupa, David
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [32] Efficacy and safety of doravirine/ islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial
    Mngqibisa, R.
    Khaertynova, I.
    Kumar, P.
    Carr, A.
    Haider, S.
    Zhang, Y.
    Correll, T.
    Asante-Appiah, E.
    Greaves, W.
    HIV MEDICINE, 2023, 24 : 196 - 197
  • [33] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    LANCET, 2021, 397 (10290): : 2151 - 2168
  • [34] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (MeasureUp 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (vol 397, pg 2151, 2021)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Katoh, Norito
    LANCET, 2021, 397 (10290): : 2150 - 2150
  • [35] Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/ emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: Week 48 results from a randomized, double-blind phase 3 trial
    Post, F. A.
    Di Perri, G.
    Cunningham, D.
    Mussini, C.
    Rockstroh, J. K.
    Correll, T. A.
    McMullan, C. J.
    Karten, M.
    Zhang, Y.
    Squires, K.
    Fox, M. C.
    Pisculli, M.
    HIV MEDICINE, 2023, 24 : 189 - 191
  • [36] Doravirine/Islatravir (100mg/0.75mg) once daily compared to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as Initial HIV-1 treatment: 48 week results from a double-blind phase 3 trial
    Rockstroh, J. K.
    Paredes, R.
    Cahn, P.
    Molina, J. -M.
    Sokhela, S.
    Hinestrosa, F.
    Kassim, S.
    Ortega, E. Valencia
    Cunningham, D.
    Ghosn, J.
    Bogner, J. R.
    Gatanaga, H.
    Asante-Appiah, E.
    Zang, Y.
    Klopfer, S. O.
    Eves, K.
    Pisculli, M. L.
    Squires, K.
    Correll, T. A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [37] Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
    Morales-Ramirez, Javier
    Bogner, Johannes R.
    Molina, Jean-Michel
    Lombaard, Johan
    Dicker, Ira B.
    Stock, David A.
    Degrosky, Michelle
    Gartland, Margaret
    Dumitresce, Teodora Pene
    Min, Sherene
    Llamoso, Cyril
    Joshi, Samit R.
    Lataillade, Max
    PLOS ONE, 2018, 13 (10):
  • [38] Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
    Eron, Joseph J.
    Orkin, Chloe
    Cunningham, Douglas
    Pulido, Federico
    Post, Frank A.
    De Wit, Stephane
    Lathouwers, Erkki
    Hufkens, Veerle
    Jezorwski, John
    Petrovic, Romana
    Brown, Kimberley
    Van Landuyt, Erika
    Opsomer, Magda
    De Wit, S.
    Florence, E.
    Moutschen, M.
    Van Wijngaerden, E.
    Vandekerckhove, L.
    Vandercam, B.
    Brunetta, J.
    Conway, B.
    Klein, M.
    Murphy, D.
    Rachlis, A.
    Shafran, S.
    Walmsley, S.
    Ajana, F.
    Cotte, L.
    Girardy, P. -M.
    Katlama, C.
    Molina, J. -M.
    Poizot-Martin, I.
    Raffi, F.
    Rey, D.
    Reynes, J.
    Teicher, E.
    Yazdanpanah, Y.
    Gasiorowski, J.
    Halota, W.
    Horban, A.
    Piekarska, A.
    Witor, A.
    Arribas, J. R.
    Perez-Valero, I.
    Berenguer, J.
    Casado, J.
    Gatell, J. M.
    Gutierrez, F.
    Galindo, M. J.
    Gutierrez, M. D. M.
    ANTIVIRAL RESEARCH, 2019, 170
1234